Recent

% | $
Quotes you view appear here for quick access.

Global Partners LP Message Board

citiccgirl 13 posts  |  Last Activity: Mar 12, 2015 1:26 PM Member since: Apr 18, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • FEYE Topeka believes FireEye shares could play "catchup" in 2015 following 2014 underperformance. The firm expects FireEye's position in Advanced Persistent Threat market, expansion of its Total Addressable Market through entry into Endpoint Protection, increased awareness of highly publicized data breaches, and operating margin expansion to drive shares.

    The firm rates FireEye a Buy with a $45 price target

    Sentiment: Strong Buy

  • GMLP Golar LNG Partners announces secondary offering of 7,170,000 common units by Golar LNG Limited

    GLNG is not doing a secondary but makes all the money :)) ..that's why you create a partner...GMLP is doing the seconday

    GMLP is GLNG's partner. GLNG is the Parent. Similar to CQP and LNG. The relationship benefits the Parent, as the partner is often used for issuing stock etc...that's why the dividend is higher for the partner, because the alliance benefits the parent.

    Sentiment: Strong Buy

  • 20-Jan-15 15:20 ET

    COMDX

    Commodities Trade: PDS Long Position Idea (5.21 -0.16)

    I'm taking a 1/3 size long position in Precision Drilling (PDS) following our news... 'Hearing sell side shop out suggesting SLB could have an interest in PDS Precision DrillingPrecision Drilling.' Please see 15:16 post.

    Following the HAL/BHI merger, which hasn't closed yet, I've been watching for names that SLB may want to acquire following that giant merger. Earlier this morning, SLB had already reported that it had taken a $1.7 bln stake in Russia's largest oil and gas driller Eurasia Drilling Co. (EDCL), Ask $5.22. More color later... bigger than average volume happening right now.



    20-Jan-15 15:16 ET

    PDS

    Precision Drilling: Hearing sell side shop out suggesting SLB could have an interest in PDS (5.06 -0.29)

    Sentiment: Strong Buy

  • These CROs are Poised For Solid Growth in Year(s) Ahead (INCR, PRAH)Anyone who has followed the IPO market over the past year or so is well aware of the barrage of development stage pharmaceutical companies going public. By our count, there were a staggering seventy-six pharmaceutical or biopharmaceutical IPOs in 2014. Furthermore, as we look at the IPO pipeline so far for 2015, there are plenty more pharmaceutical IPOs readying to go public. With so many companies raising capital to finance clinical trials, this should bode especially well for contract research organizations (CROs) which generate revenue by assisting in and conducting clinical trials for pharmaceutical and medical device companies.

    There have been two recent IPOs in the CRO field in recent weeks: INC Research (INCR) and PRA Health Sciences (PRAH). Both have performed well out of the gate, up 28% and 29% respectively, with INCR showing notable relative strength of late. While these may not be "homerun-type" names, we do feel that each offer solid longer-term investment opportunities due to the favorable trends underlying their businesses. In a volatile market, companies like INCR and PRAH -- which have strong backlogs -- may look more and more attractive to a growing number of investors.

    Here is a closer look at each company:

    For some background, INCR solely focuses on Phase 1 to Phase 4 clinical trials for biopharmaceutical and medical device companies. The company is particularly focused on trials surrounding the Central Nervous System, oncology, and complex diseases such as genetic disorders and infectious disease. Based on industry data, INCR estimates that these areas represent over 55% of total Phase 3 drugs under development

    Sentiment: Strong Buy

  • citiccgirl citiccgirl Jan 22, 2015 5:02 PM Flag

    Over the past several years, the company has increased its exposure to large biopharmaceutical companies through acquisitions and organic means, providing it with the opportunity to compete for large late-stage clinical development trials. In 2013, about 57% of its revenue was attributed to large biopharmaceutical companies. Its proprietary "Trusted Process" operating model provides it with a competitive advantage. Namely, the model standardizes methodologies, increases the predictability of the delivery of its services, and reduces operational risk.

    the industry climate is favorable for INCR as biopharmaceutical companies continue to outsource clinical trials -- particularly in complex, high-growth therapeutic areas. To put the opportunity into context, the company estimates that total biopharmaceutical spending on drug development in 2013 was about $75 billion and will grow 3-4% annually through 2018. Furthermore, INCR believes that the market for CRO services for Phase 1 - Phase 4 development services will grow at a rate of 8-9% through 2018.

    Sentiment: Strong Buy

  • Breaks

    February 11, 2015

    10:16 EDT GLNG

    Golar LNG upgraded to Buy from Sell at ABN Amro (pre-open)
    Pre-open, ABN Amro upgraded Golar LNG to Buy based on valuation and progress made in the FLNG space. Price target $38

    Sentiment: Strong Buy

  • vGLNG is going to follow OIL & USO tick to pre-market highs in recent trade with CLh5 now 52.78 +1.57

    Sentiment: Strong Buy

  • THE NEXT BIG THING | Updated: 24-Feb-15 | Archive
    Analysis of upcoming IPOs and spin-offs, as well as secondary plays on highly-anticipated new issues.

    INC Research (INCR): Strong Quarter Bolsters Bullish Sentiment

    Before the open, INC Research (INCR) issued its Q4 earnings, its first quarterly report since going public on November 7, 2014. The company handily surpassed the top and bottom line estimates and issued FY15 EPS and revenue guidance that is above consensus at the mid-point of the range.  The results have popped shares higher by as much #$%$. 

    A week earlier, its CRO peer PRA Health Sciences (PRAH) -- which went public a week after INCR -- delivered its Q4 results, also exceeding the consensus estimates, providing an indication that INCR might follow suit with a solid report. With both companies outperforming expectations, it is also further evidence that the CRO industry is buzzing with activity.

    Sentiment: Strong Buy

  • citiccgirl citiccgirl Feb 24, 2015 1:05 PM Flag

    Guidance & Outlook

    • INCR guided for EPS of $1.19-$1.29 vs. the $1.20 Capital IQ Consensus. At the mid-point, this would be $1.24 vs. $1.20. For revenue, INCR projected $870-$900 million vs. the $879.23 million. Again, this is above consensus at the mid-point, $885 million vs. $879.23 million.

    • On a growth basis, this would equate to year/year EPS growth of 49% and revenue growth of 9%.

    • In our past reports on INCR and PRAH, we have discussed how the ramping activity for clinical trials has provided a sharp pick-up in demand for CROs. Additionally, many pharmaceutical and biotech companies are finding it more cost effective to hire CROs to conduct trials. This trend continues to play out as INCR's backlog grew 7$ in FY14 to $1.6 billion. The company noted during its conference call that the most recent market studies continue to estimate the market for CRO services for Phase 2-Phase 4 clinical development to grow in the high single digits over the next three to five years.

    • From a more company-specific standpoint, INCR's acquisition and integration of MEK consulting in 1H14 has also provided a catalyst, expanding its reach and footprint in several geographies like Greece, Turkey, the Middle East, North Africa, and Japan.

    Sentiment: Strong Buy

  • citiccgirl citiccgirl Feb 24, 2015 1:06 PM Flag

    Valuation

    • Given its double-digit earnings growth potential, INCR's valuation looks reasonable in our view. At the moment, it is trading with a 1-year forward P/E of 21.8x (using the mid-point of its guidance) and a 1-year forward P/S of 1.8x. Meanwhile, PRAH is trading at 20.5x and 1.2x, also quite reasonable.

    Conclusion

    INCR's solid Q4 report and guidance bolsters are bullish stance on the stock as demand for its services remains very healthy. While INCR won't be confused for a young, up-and-coming tech company growing the topline by triple digits, it should be poised for solid double-digit earnings growth over the foreseeable future.

    After reaching post-IPO highs in mid-January, the stock tumbled lower over the following month before stabilizing in the $22.50 areas. Since then, the stock has been strong, up nearly 20%. There is resistance in the $28 area that traders should be mindful of, but, if it can push past that level to trade to new post-IPO highs, the stock could gain additional attention from traders.

    All in all, we view INCR as a solid intermediate term investment opportunity.

    Sentiment: Strong Buy

  • 24-Feb-15 06:22

    INCR
    INC Research Holdings beats by $0.05, beats on revs; guides FY15 EPS above consensus, revs in-line

    Reports Q4 (Dec) earnings of $0.26 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus Estimate of $0.21; revenues rose 22.5% year/year to $213.7 mln vs the $207.55 mln consensus. Net new business awards of $316.3 million, representing growth of 10.9% and a book-to-bill ratio of 1.5x.

    Co issues guidance for FY15, sees EPS of $1.19-1.29 vs. $1.20 Capital IQ Consensus; sees FY15 revs of $870-900 mln vs. $879.23 mln Capital IQ Consensus Estimate.

    Sentiment: Strong Buy

  • Story Stocks: Invitae (NVTA) - Genetic Testing Company Reports Q4 Results, Lists Key Indicators of Success

    Invitae, a provider of genetic info to mainstream medical practices, reported fourth quarter and year-end results after the close on Tuesday. Results from the quarter included EPS of ($16.75) on revenues of $0.876 million.However, its worth noting that the company is still in the developmental stage, and in light of this, NVTA provided other key indicators of success.

    First, in case you're not familiar with NVTA, Invitae is focused on making comprehensive genetic testing more affordable and accessible. Its goal is to consolidate the majority of the world's genetic tests into a single service, then ultimately providing that service at a lower price and faster turnaround time than most single gene tests currently available.

    NVTA launched its first commercial offering in late Nov 2013. The company initially charged $1,500 per sample, and allowed clients to receive test results on any or all of the 216 genes tested in the multi-gene panels. Previously, customers would need to have several tests done to test different genes, and would incur separate costs for each additional test.

    Turning to the key indicators of success, the first thing that jumps out is the decrease in average cost per billable from $1,500 to under $1,200. Additionally, NVTA secured reimbursement contracts with Blue Shield of California and SelectHealth, and became licensed for Medicare, which should help speed up the collection period and generate more cash flow. Lastly, while revenues grew nearly 900% year/year in fourth quarter 2014, total costs and operating expenses grew just 27% over the same period. Although a 900% revenue growth rate is not sustainable over the long term, and the sample size thusfar is small, it is a positive to see revenues increasing at a faster rate than expenses.

    Sentiment: Strong Buy

  • Reply to

    NVTA From Briefing ..they love this IPO

    by citiccgirl Mar 12, 2015 1:25 PM
    citiccgirl citiccgirl Mar 12, 2015 1:26 PM Flag

    Looking ahead, NVTA plans to continue reducing its cost of goods sold while also increasing test volumes and improving reimbursement and cash collections. NVTA provided guidance for 2015 of delivering 14,000-17,000 billable tests to its customers. In addition, the company expects to increase its test menu to cover more than 500 genes (currently offers testing for 216 genes).

    Sentiment: Strong Buy

GLP
34.92+0.39(+1.13%)Mar 27 4:02 PMEDT